Skip to content

BridgeBio Pharma, Inc.

BBIO

CIK 0001743881

← back to feed
Revenue (TTM)
$542.41M
+126.3% YoY Q1 Apr 2026
Net Income (TTM)
—
Q1 Apr 2026
EPS Diluted (TTM)
−$3.62
−31.3% YoY Q1 Apr 2026
Gross Margin
95.8%
Q1 Apr 2026
Operating Margin
-90.3%
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
−$761.15M
Q1 Apr 2026
Cash
$879.89M
Q1 Apr 2026
Total Debt
$3.65M
Q1 Apr 2026
Shares Outstanding
195.86M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings